☰

Christal D. Sohl, Ph.D. - Publications

Affiliations: 
2005-2010 Biochemistry Vanderbilt University, Nashville, TN 
 2010-2015 Pharmacology Yale University School of Medicine, New Haven, CT 
 2015- Biochemistry San Diego State University, San Diego, CA, United States 
Area:
Biochemistry
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Sohl CD, Matteo DA, Wells G, Luna L, Upadhye V, Quichocho G, Chambers JM, Miller W, Scott D, Schiffer JM. The Catalytic Features of IDH1 Mutations Can Drive Neomorphic Activity, Phenotype Severity, and Inhibitor Binding The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.01939  0.41
2019 Chambers J, Miller W, Quichocho G, Upadhye V, Matteo DA, Bobkov A, Sohl C, Schiffer JM. Water networks and correlated motions in mutant IDH1 are critical for allosteric inhibitor binding and activity. Biochemistry. PMID 31869219 DOI: 10.1021/Acs.Biochem.9B01023  0.428
2019 Kennedy MA, Xu Z, Wu Y, Sohl CD. A Tie2 kinase mutation causing venous malformations increases phosphorylation rates and enhances cooperativity. Biochemical and Biophysical Research Communications. PMID 30638931 DOI: 10.1016/J.Bbrc.2019.01.020  0.386
2019 Weeks JL, Wells G, Alexander S, Metallo C, Sohl CD. Abstract 4381: Investigating the reversible MDH1 catalytic reaction in squamous non-small cell lung cancer Cancer Research. 79: 4381-4381. DOI: 10.1158/1538-7445.Am2019-4381  0.311
2018 Ryan MR, Sohl CD, Luo B, Anderson KS. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT. Molecular Cancer Research : McR. PMID 30257990 DOI: 10.1158/1541-7786.Mcr-18-0429  0.559
2018 Matteo DA, Wells GA, Luna LA, Grunseth AJ, Zagnitko O, Scott DA, Hoang A, Luthra A, Swairjo MA, Schiffer JM, Sohl CD. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. The Biochemical Journal. PMID 30249606 DOI: 10.1042/Bcj20180424  0.432
2017 Matteo DA, Grunseth AJ, Gonzalez ER, Anselmo SL, Kennedy MA, Moman P, Scott DA, Hoang A, Sohl CD. Molecular Mechanisms of Isocitrate Dehydrogenase 1 (IDH1) Mutations Identified in Tumors: The Role of Size and Hydrophobicity at Residue 132 on Catalytic Efficiency. The Journal of Biological Chemistry. PMID 28330869 DOI: 10.1074/Jbc.M117.776179  0.42
2015 Sohl CD, Szymanski MR, Mislak AC, Shumate CK, Amiralaei S, Schinazi RF, Anderson KS, Yin YW. Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ. Proceedings of the National Academy of Sciences of the United States of America. 112: 8596-601. PMID 26124101 DOI: 10.1073/Pnas.1421733112  0.547
2015 Sohl CD, Ray S, Sweasy JB. Pools and Pols: Mechanism of a mutator phenotype. Proceedings of the National Academy of Sciences of the United States of America. 112: 5864-5. PMID 25931524 DOI: 10.1073/Pnas.1505169112  0.303
2015 Sohl CD, Ryan MR, Luo B, Frey KM, Anderson KS. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. Acs Chemical Biology. 10: 1319-29. PMID 25686244 DOI: 10.1021/Acschembio.5B00014  0.7
2015 Sohl CD, Ryan M, Luo B, Frey K, Anderson KS. Abstract 2436: Understanding the molecular mechanism of targeted kinase inhibitor resistance mediated by the FGFR1 gatekeeper mutation Cancer Research. 75: 2436-2436. DOI: 10.1158/1538-7445.Am2015-2436  0.691
2015 Sohl CD, Ryan MR, Luo B, Frey KM, Anderson KS. Illuminating the molecular ,mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: The Achilles' heel of targeted therapy Acs Chemical Biology. 10: 1319-1329. DOI: 10.1021/acschembio.5b00014  0.674
2014 Towle-Weicksel JB, Dalal S, Sohl CD, Doublie S, Anderson KS, Sweasy JB. Fluorescence resonance energy transfer studies of DNA polymerase β the critical role of fingers domain movements and a novel non-covalent step During nucleotide selection Journal of Biological Chemistry. 289: 16541-16550. PMID 24764311 DOI: 10.1074/Jbc.M114.561878  0.475
2014 Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS. Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics. Antiviral Research. 106: 1-4. PMID 24632447 DOI: 10.1016/J.Antiviral.2014.03.001  0.516
2013 Sohl CD, Kasiviswanathan R, Copeland WC, Anderson KS. Mutations in human DNA polymerase γ confer unique mechanisms of catalytic deficiency that mirror the disease severity in mitochondrial disorder patients. Human Molecular Genetics. 22: 1074-85. PMID 23208208 DOI: 10.1093/Hmg/Dds509  0.506
2012 Cheng Q, Sohl CD, Yoshimoto FK, Guengerich FP. Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4. The Journal of Biological Chemistry. 287: 29554-67. PMID 22773874 DOI: 10.1074/Jbc.M112.390047  0.479
2012 Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS. Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase. Molecular Pharmacology. 82: 125-33. PMID 22513406 DOI: 10.1124/Mol.112.078758  0.537
2012 Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS. Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity. Antimicrobial Agents and Chemotherapy. 56: 1630-4. PMID 22155823 DOI: 10.1128/Aac.05729-11  0.505
2011 Guengerich FP, Sohl CD, Chowdhury G. Multi-step oxidations catalyzed by cytochrome P450 enzymes: Processive vs. distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms. Archives of Biochemistry and Biophysics. 507: 126-34. PMID 20804723 DOI: 10.1016/J.Abb.2010.08.017  0.627
2010 Sohl CD, Guengerich FP. Kinetic analysis of the three-step steroid aromatase reaction of human cytochrome P450 19A1. The Journal of Biological Chemistry. 285: 17734-43. PMID 20385561 DOI: 10.1074/Jbc.M110.123711  0.485
2009 Cheng Q, Sohl CD, Guengerich FP. High-throughput fluorescence assay of cytochrome P450 3A4. Nature Protocols. 4: 1258-61. PMID 19661996 DOI: 10.1038/Nprot.2009.123  0.475
2009 Sohl CD, Cheng Q, Guengerich FP. Chromatographic assays of drug oxidation by human cytochrome P450 3A4. Nature Protocols. 4: 1252-7. PMID 19661995 DOI: 10.1038/Nprot.2009.122  0.47
2009 Guengerich FP, Martin MV, Sohl CD, Cheng Q. Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nature Protocols. 4: 1245-51. PMID 19661994 DOI: 10.1038/Nprot.2009.121  0.446
2008 Isin EM, Sohl CD, Eoff RL, Guengerich FP. Cooperativity of cytochrome P450 1A2: interactions of 1,4-phenylene diisocyanide and 1-isopropoxy-4-nitrobenzene. Archives of Biochemistry and Biophysics. 473: 69-75. PMID 18328798 DOI: 10.1016/J.Abb.2008.02.033  0.463
2008 Sohl CD, Isin EM, Eoff RL, Marsch GA, Stec DF, Guengerich FP. Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2: highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding. The Journal of Biological Chemistry. 283: 7293-308. PMID 18187423 DOI: 10.1074/Jbc.M709783200  0.493
2006 Wu ZL, Sohl CD, Shimada T, Guengerich FP. Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Molecular Pharmacology. 69: 2007-14. PMID 16551781 DOI: 10.1124/Mol.106.023648  0.477
Show low-probability matches.